Warfarin monitoring in ambulatory older individuals receiving antimicrobial therapy

Pharmacotherapy

Volumn 25, Issue 8, 2005, Pages 1055-1061

  Raebel, Marsha A ^a,c   Witt, Daniel M ^b,c   Carroll, Nikki M ^a   Magid, David J ^a,d  

^a CLINICAL RESEARCH UNIT   (United States)

^b University of Colorado ^*  (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Antibiotic; Antimicrobial; Elderly; INR; International normalized ratio; Managed care; Warfarin

Indexed keywords

ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; CEFAMANDOLE; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CIPROFLOXACIN; DEMECLOCYCLINE; DICLOXACILLIN; DOXYCYCLINE; ERYTHROMYCIN; FLUCONAZOLE; GRISEOFULVIN; ISONIAZID; ITRACONAZOLE; KETOCONAZOLE; LATAMOXEF; MACROLIDE; METRONIDAZOLE; MICONAZOLE; NAFCILLIN; NORFLOXACIN; OFLOXACIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFAFURAZOLE; SULFAMETHOXAZOLE; SULFONAMIDE; TETRACYCLINE DERIVATIVE; UNINDEXED DRUG; WARFARIN;

AGED; ANTIMICROBIAL THERAPY; ARTICLE; CLINICAL PRACTICE; COHORT ANALYSIS; DRUG MONITORING; FEMALE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PHARMACY; PRESCRIPTION; RETROSPECTIVE STUDY; RISK MANAGEMENT;

AGED; AMBULATORY CARE; ANTI-INFECTIVE AGENTS; ANTICOAGULANTS; COHORT STUDIES; DRUG INTERACTIONS; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MONITORING, PHYSIOLOGIC; PRESCRIPTIONS, DRUG; QUALITY OF HEALTH CARE; RETROSPECTIVE STUDIES; WARFARIN;

EID: 23244455091     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.2005.25.8.1055     Document Type: Article

References (31)

1. Haines ST, Racine E, Zeolla M. Venous thromboembolism. In: DiPiro JT, Talbert RL, Yee GC, et al, eds. Pharmacotherapy, a pathophysiologic approach. New York: McGraw-Hill, 2002:337-73.
2. Anonymous. Warfarin. Drug-Reax. Interactive drug interactions. Micromedex Healthcare Series. Greenwood Village, CO: Thomson Micromedex, 2004.
3. Seaton TL, Celum CL, Black DJ. Possible potentiation of warfarin by fluconazole. Drug Intell Clin Pharm 1990;24:1177-8.
4. Lazar JD, Wilner KD. Drug interactions with fluconazole. Rev Infect Dis 1990;12(suppl 3):S327-33.
5. Black DJ, Kunze KL, Wienkers LC, et al. Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies. Drug Metab Dispos 1996;24:422-8.
6. Gericke KR. Possible interaction between warfarin and fluconazole. Pharmacotherapy 1993;13:508-9.
7. Ellis RJ, Mayo MS, Bodensteiner DM. Ciprofloxacin-warfarin coagulopathy: a case series. Am J Hematol 2000;63:28-42.
8. Ellis KW, Smith EA, Baddour LM. Immediate potentiaion of the hypoprothrombinemic response of warfarin by fluconazole. Infect Dis Clin Pract 1999;8:351-4.
9. Kaufman JM, Fauver HE Jr. Potentiaion of warfarin by trimethoprim- sulfamethoxazole. Urology 1980;16:601-3.
10. O'Reilly RA. Stereoselective interaction of trimethoprim-sulfamethoxazole with the separated enantiomorphs of racemic warfarin in man. N Engl J Med 1980;302:33-5.
11. Greenlaw CW. Drug interaction between co-trimoxazole and warfarin [letter]. Am J Hosp Pharm 1979;36:1155-6.
12. Errick JK, Keyes PW. Co-trimoxazole and warfarin: a case report of an interaction. Am J Hosp Pharm 1978;35:1399-401.
13. Tilstone WJ, Gray JM. Interaction between warfarin and sulphamethoxazole. Postgrad Med J 1977;53:388-90.
14. Serlin MJ, Breckenridge AM. Drug interactions with warfarin. Drugs 1983;25:610-20.
15. Hassell D, Utt JK. Suspected interaction: warfarin and erythromycin. South Med J 1985;78:1015-16.
16. Weibert RT, Lorentz SM, Townsend RJ, Cook CE, Klauber MR, Jagger PI. Effect of erythromycin in patients receiving long-term warfarin therapy. Clin Pharm 1989;8:210-14.
17. Sato RI, Gray DR, Brown SE. Warfarin interaction with erythromycin. Arch Intern Med 1984;144:2413-14.
18. Schwartz J, Bachmann K, Perrigo E. Interaction between warfarin and erythromycin. South Med J 1983;76:91-3.
19. Roerig Division of Pfizer, Inc. Diflucan (fluconazole) product information. New York, NY; 1999.
20. Bayer Pharmaceutical Corporation. Cipro XR (ciprofloxacin extended-release tablets) product information. West Haven, CT; 2003.
21. Hutten BA, Lensing AW, Kraaijenhagen RA, Prins MH. Safety of treatment with oral anticoagulants in the elderly: a systematic review. Drugs Aging 1999;14:303-12.
22. Launbjerg J, Egeblad H, Heaf J, Nielsen HN, Fugleholm AM. Bleeding complications to oral anticoagulant therapy: multivariate analysis of 1010 treatment-years in 551 outpatients. J Intern Med 1991;229:351-5.
23. Landefeld CS, Goldman I. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989;87:144-52.
24. Fihn SD, Callahan CM, Martin DC, McDonnell MB, Henikoff JG, White RH. The risk and severity of bleeding complications in elderly patients treated with warfarin. Arch Intern Med 1996;124:970-9.
25. Froom P, Miron E, Barak M. Oral anticoagulants in the elderly. Br J Hematol 2002;120:526-8.
26. Casner PR, Sandoval E. Increased sensitivity to warfarin in elderly hispanics. J Clin Pharmacol 2002;42:145-50.
27. Gurwitz JH, Avorn J, Ross-Degan D, Choodnovsky I, Ansell J. Aging and the anticoagulant response to warfarin therapy. Ann Intern Med 1992;116:901-4.
28. Wittkowsky AK, Whitely KS, Devine EB, Nutescu E. Effect of age on international normalized ratio at the time of major bleeding in patients treated with warfarin. Pharmacotherapy 2004;24:600-5.
29. Knight EL, Avorn J. Quality indicators for appropriate medication use in vulnerable elders. Ann Intern Med 2001;135(8 pt 2):703-10.
30. Storey JD. A direct approach to false discovery rates. J R Statist Soc B 2002;64(pt 3):479-98.
31. Witt DM, Tillman DJ. Clinical pharmacy anticoagulation services in a group model health maintenance organization. Pharm Pract Manag Q 1998;18:34-55.